Meag Munich Ergo, Kapitalanlagegesellschaft Mb H Bei Gene, Ltd. Transaction History

Meag Munich Ergo, Kapitalanlagegesellschaft Mb H

$3.1 Billion
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 18, 2022	BUY	$131.8 - $202.24 $474,480 - $728,064	3,600 New	3,600 $485,000
Q2 2022 Jul 19, 2022	SELL	$121.11 - $216.05 $84,777 - $151,235	-700 Closed	0 $0
Q1 2022 Apr 13, 2022	SELL	$146.52 - $269.56 $952,380 - $1.75 Million	-6,500 Reduced 90.28%	700 $134,000
Q2 2021 Jul 16, 2021	BUY	$292.75 - $367.01 $614,775 - $770,721	2,100 Added 41.18%	7,200 $2.47 Million
Q1 2021 Apr 20, 2021	BUY	$260.64 - $382.12 $1.02 Million - $1.49 Million	3,900 Added 325.0%	5,100 $1.78 Million
Q4 2020 Jan 20, 2021	SELL	$221.31 - $316.61 $553,275 - $791,525	-2,500 Reduced 67.57%	1,200 $306,000
Q1 2020 Apr 23, 2020	SELL	$121.84 - $173.19 $2.68 Million - $3.81 Million	-22,000 Reduced 85.6%	3,700 $456,000
Q4 2019 Jan 17, 2020	BUY	$115.78 - $208.34 $416,808 - $750,024	3,600 Added 16.29%	25,700 $4.28 Million
Q4 2018 Jan 29, 2019	BUY	$107.01 - $175.15 $2.36 Million - $3.87 Million	22,100 New	22,100 $3.06 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$2.03 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.24 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$995 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$956 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$712 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $19.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meag Munich Ergo, Kapitalanlagegesellschaft Mb H, based on Form 13F filings with the SEC.

News

Stay updated on Meag Munich Ergo, Kapitalanlagegesellschaft Mb H with notifications on news.

Account